We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Craneware Plc | LSE:CRW | London | Ordinary Share | GB00B2425G68 | ORD 1P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
2,300.00 | 2,450.00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Prepackaged Software | USD 189.27M | USD 11.7M | USD 0.3293 | 71.36 | 835.24M |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
- | O | 0 | 2,350.00 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
29/11/2024 | 16:18 | UK RNS | Craneware plc Dividend Currency Election |
20/11/2024 | 13:57 | UK RNS | Craneware plc Holding(s) in Company |
19/11/2024 | 17:13 | UK RNS | Craneware plc Vesting of Long Term Incentive Plan Awards and TVR |
13/11/2024 | 13:23 | UK RNS | Craneware plc Result of AGM |
13/11/2024 | 12:00 | ALNC | IN BRIEF: Craneware says US hospitals can spend again after election |
13/11/2024 | 07:00 | UK RNS | Craneware plc AGM Statement and Board Changes |
25/10/2024 | 14:02 | UK RNS | Craneware plc Holding(s) in Company |
16/10/2024 | 16:05 | UK RNS | Craneware plc Posting of Annual Report and Notice of AGM |
15/10/2024 | 06:00 | UK RNS | Craneware plc Block listing Interim Review |
02/10/2024 | 11:30 | UK RNS | Craneware plc Total Voting Rights |
Craneware (CRW) Share Charts1 Year Craneware Chart |
|
1 Month Craneware Chart |
Intraday Craneware Chart |
Date | Time | Title | Posts |
---|---|---|---|
06/12/2024 | 12:29 | Craneware for Healthcare | 156 |
06/7/2016 | 10:59 | Craneware - poised to benefit from Obama healthcare reforms | 59 |
22/2/2010 | 17:31 | Summat called Craneware, Supposedly | 31 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
2024-12-11 17:15:00 | 2,350.00 | 5,000 | 117,500.00 | O |
2024-12-11 17:15:00 | 2,350.00 | 5,000 | 117,500.00 | O |
2024-12-11 17:15:00 | 2,350.00 | 7,500 | 176,250.00 | O |
2024-12-11 16:38:29 | 2,400.00 | 600 | 14,400.00 | O |
2024-12-11 16:38:22 | 2,350.00 | 5,000 | 117,500.00 | O |
Top Posts |
---|
Posted at 11/12/2024 08:20 by Craneware Daily Update Craneware Plc is listed in the Prepackaged Software sector of the London Stock Exchange with ticker CRW. The last closing price for Craneware was 2,350p.Craneware currently has 35,542,169 shares in issue. The market capitalisation of Craneware is £835,240,972. Craneware has a price to earnings ratio (PE ratio) of 71.36. This morning CRW shares opened at - |
Posted at 30/10/2024 16:03 by kemche Took its time.kemche - 23 Jun 2022 - 14:14:06 - 112 of 152 Craneware for Healthcare - CRW Next one to be taken out? |
Posted at 16/10/2024 10:55 by robe7 Anybody know the reason for the fall in price - were there's smoke there's usually fire but ? |
Posted at 09/9/2023 06:19 by mammyoko Looking firm for a return to > £20? Some large volumes this week prior to and after results. Confident outlook from Neilson - post-covid problems abating enabling hospitals to start to consider investing to optimise spend.The dataset obtained by CRW would have huge potential value to a trade buyer. I could easily see this being bought in the next 12 months. Companies in this sector such as EMIS, INS and ERGO with structural growth opportunities all recently bid for. |
Posted at 12/4/2023 10:25 by rimau1 I got excited when i saw the share buyback programme until i read it. £5m to hold shares in treasury for future share payments to directors, not really a buyback in my book. No size to shift the needle and no cancellation. All talk sadly. Remains on the watchlist. |
Posted at 15/2/2022 18:10 by km18 ...from last year....Company overview: Today’s company provides healthcare institutions with something crucial for the long-term prosperity of such entities – optimization of financial and operational performance. The firm argues that roughly $22 million in revenue are not captured from the average 350-bed hospital, and that is a lot even in the world of hyper expensive testing and analysis robots a modern hospital has. Craneware’s ambition is to reduce the foregone profits through its cycle experts and innovative technology which ensure transparency. They have 11 key products in their portfolio, which tackle different parts of the revenue generation cycle of each hospital. The company was founded in 1999 and currently has offices in UK and USA ad serves more than 1/3rd of the registered hospitals on US soil. The company is growing organically, without any big acquisitions during the past 10 years. Goodwill for the period ending June 2021 was at $11.1m, or 3% which is negligible. Growth in the fundamentals is strong, with revenue CAGR of 8.68% and EPS at 4.06%. Return on capital employed is growing at 25.5% on compound basis and net gearing is negative. Return on equity is in the top quartile of the industry at 7.9% and dividends are growing at 11.6% CAGR. Today they have released their final results for the FY 2021 (ending in June). Revenue swelled by 6% reaching $75.6m. PBT is below last year’s figures at $13.2m due to exceptional costs from the acquisition they did. As a result, EPS is down on 2020 figures to 48.1 cents. They have increased their expenditures on R&D and proposed an increase in dividends from 18.45 cents to 21.47 cents. Outlook is positive and momentum in sales is sustained in the new financial period. Management is “ confident in return to double digit organic growth”....fro |
Posted at 09/6/2021 07:07 by rimau1 The good news for private investors is that you can now buy below the placing price. High quality company and i am happy to buy back having exited last year. £21.50 and i will add more if it falls further, acquisition looks compelling given that only 33% of Sentry customers are existing CRW clients. Given high barriers to entry this is a huge cross selling opportunity. |
Posted at 08/6/2021 11:10 by jombaston They have shown scant regard for the principles of pre-emption and yet they have the nerve to put out this statement:"Craneware consulted with a number of its major shareholders prior to the Placing and has respected the principles of pre-emption through the allocation process. The Company is pleased by the support it has received from both existing and new shareholders." Of course, all the major shareholders knew this was coming hence the drift down in the share price. But not to save even a small amount for private investors is very disappointing especially for a 23% dilution. I might buy some more except I haven't seen or heard the presentation that the institutions have. Last year Diploma, a FTSE 250 member and much bigger company than CRW, made a 10% equity raise for an acquisition and gave shareholders a chance to buy through PrimaryBid. Why can't these guys do this? I agree it would be nice for all shareholders to be treated equally but shouldn't it be mandatory? |
Posted at 20/4/2021 20:28 by jonut Rush of blood to bonce yesterday when CRW broke through my upper trend line at £25.50.Broker wouldn't give an online quote so settled on a limit at 25.50. Ask was at 26 within 10 minutes. Disinclined to increase, I left it expecting CRW to carry on up.Close of business showed my limit accepted! Today the ask remained at £26 but the bid dropped to 24.50. Chanced a quote, to be bid 25.60 and took it. I should, of course be buying when the price falls through the bottom trend line but it does make you wonder what the MM's are playing at. Looking at the trades today, there are lots ~25.50 marked as buys. Nearly made a quid anyway. |
Posted at 20/1/2021 08:58 by rimau1 Good solid update. I have sold out this morning mainly because of US dollar earnings exposure and the share price has rerated over the past 6 months, high quality company and i will reinvest if it falls back during the year. |
Posted at 16/11/2020 10:36 by jonut AGM tomorrow. share price up about 25% over the last month on thinnish volumes. On dummy trades, bid is usually at the mid price. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions